Lexapro “approvable” for GAD
Executive Summary
Forest still anticipates early 2004 launch of generalized anxiety disorder indication for Lexapro despite Sept. 26 "approvable" letter from FDA. Supplemental NDA for panic disorder submitted April 30, 2002 not affected by GAD setback, Forest says. The company also plans an early 2004 filing for social anxiety disorder...